Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034065 (pulmonary embolism)
 14,979 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

38-years-old female patient was referred to the Pulmonary Diseases Ward because of suspicion of the right lung infiltrative tuberculosis. Anamnesis included cervical carcinoma treated surgically two years earlier. Neither radio- nor chemotherapy was applied. Infectious etiology was not confirmed. Lab tests, bronchoscopy and abdominal USG did not show any abnormalities. Contributory anamnesis, cardiorespiratory failure, variability of X-ray picture, enlargement of the heart in subsequent X-ray examinations suggested chronic pulmonary embolism. Large tumor masses were seen within the right ventricule on USG examination. The patient died in the course of the surgical procedure. Grey-yellow, elastic masses remaining in pulmonary arteries and between trabeculae carneae were found on autopsy. Enlarged and infiltrated paraaortic and iliac lymph nodes were observed. Planoepithelial nonkeratinizing carcinoma cells were confirmed in the above mentioned masses.
Pneumonol Alergol Pol 1996
PMID:[Implantation of cervix neoplasms in the right heart ventricle as the cause of chronic pulmonary embolism]. 898 47

A case of venous aneurysm of the posterior tibial vein secondary to stab injury that resulted in A-V fistula in a 23 year male patient is presented. Popliteal venous aneurysm both of congenital as well as of acquired origin is a rare vascular entity that may be a potential source of thromboembolism. Thus surgery is usually required. In the presented case no history of pulmonary embolism was present. The aneurysm was treated surgically with good postoperative results.
Mater Med Pol
PMID:Aneurysm of the posterior tibial vein. A case report. 908 31

In the Department of Medicine at the Institute of Tuberculosis and Lung Diseases 50 LGM inferior vena cava filters have been inserted since 1993. Indications for filters placement were as follows: recurrent pulmonary embolism (PE) despite anticoagulation-16 patients (pts), severe bleeding complications of thrombolytic or anticoagulant therapy-9 pts, contraindications for thrombolytic and/or anticoagulant treatment-3 pts, massive PE-6 pts, chronic thromboembolic-major vessel pulmonary hypertension (CTEPH)-18 pts, extensive deep vein thrombosis of lower limbs or vena cava inferior in patients with urgent indications for surgery-10 pts. In every patient diagnostic procedures were performed after 1, 3, 6, 12, 24 and 36 months of follow-up period. Only one non-fatal episode of recurrent PE was documented. Other complications were rare and insignificant. The LGM inferior vena cava filters are effective and safe in such selectively chosen group of patients.
Pneumonol Alergol Pol 1996
PMID:[LGM inferior vena cava filters--follow up 50 patients]. 918 82

CTEPH have not been widely recognised until recently. Introduction of the new, sophisticated, non-invasive diagnostic tools accounts for rapid progress in that field. Patients with high pulmonary hypertension have a very poor prognosis. Medical treatment (vasodilators, anticoagulants) does not change outcome. Pulmonary thromboendarterectomy is the only therapeutic option for the patients. It is essential to prevent further episodes of pulmonary embolism both over the long term and during the high risk perioperative period by means of inferior vena cava filters. In the Department of Medicine, Institute of Tuberculosis and Lung Diseases 18 LGM ivc filters have been inserted in patients with CTEPH since 1994. In 7 patients PTE was performed-in 5 cases good result was achieved, 2 patients died after surgery. In the latter group 5 patients died mainly because of severe heart failure. Only one non-fatal episode of pulmonary embolism was observed. It should be concluded that the LGM ivc filters are safe and effective in preventing episodes of pulmonary embolism in patients with CTEPH.
Pneumonol Alergol Pol 1996
PMID:[Implantation of LGM inferior vena cava filters in patients with chronic pulmonary hypertension during a course of major vessel thromboembolism--observation of 18 patients]. 918 83

12 patients (7 male and 5 female) with confirmed pulmonary embolism (PE) with: angiography-5 cases, conventional contrast-enhanced CT-2 cases, echocardiography-2 cases, autopsy-3 cases were diagnosed as clinically acute PE. Criteria of clinically acute PE were: cardiac arrest-1 case-2 cases, shock-1 case, acute cor pulmonale-9 cases and acute cor pulmonale with shock. All patients were treated with heparin, administered with therapeutic prolongation of aPTT. Clinically acute PE (if possible confirmed with angiography, TC and/or echocardiography) was treated with rtPA administered in 10 minutes lasting bolus in doses 0.6-0.8 mg per kg of body weight (50 mg of rtPA during 10 minutes administered into peripheral veins). In 9 patients with pulmonary hypertension, significant decrease of tricuspidal gradient (measured echocardiographically during several hours after administration of rtPA) was documented. Improvement in PaO2, SaO2 and decrease of heart rate and respiratory rate were also achieved. No serious bleeding complications were observed after mentioned treatment. Control investigations (conventional contrast-enhanced CT and spiral CT) performed several days after rtPA administration revealed thrombus in pulmonary artery. We conclude: I rtPA administered in bolus simultaneously with heparin significantly decreased pulmonaryhypertension; rtPA administered simultaneously with heparin is safe method of treatment of PE; hemodynamic improvement after administration of rtPA is not univocal with full fibrynolitic effect.
Pneumonol Alergol Pol 1996
PMID:[Low doses of rtPA administered as a bolus in treatment of clinically acute massive pulmonary embolism]. 918 84

In 18 patients with proximal deep venous thrombosis (PDVT) confirmed by phlebography, no symptoms and signs of pulmonary embolism (PE) were observed. All patients were treated with nadroparin. During first 6 days of treatment in all patients perfusion lung scans were performed. 8 patients (44.4%) of all group developed lung scans positive for PE (silent PE). Period of successful treatment of PDVT was 10 days. No evidence of recurrent PE were observed during the period of treatment. We conclude that: 1. Frequency of silent PE in patients with PDVT is very high-lack of symptoms and signs of PE does not exclude the presence of PE in this group of patients. 2. In all patients with PDVT perfusion lung scan should be performed even in cases with no symptoms and signs of PE. 3. Low molecular weight heparins administered subcutaneously are effective in treatment either silent PE or PDVT.
Pneumonol Alergol Pol 1996
PMID:[Clinically silent pulmonary embolism in patients with proximal deep venous thrombosis]. 918 85

57 years old woman with clinically acute massive pulmonary embolism confirmed by CT enhanced by contrast administration was treated with very low dose of rtPA (0.33 mg/kg) simultaneously with constant infusion of heparin (with therapeutic prolongation of aPTT). Excellent clinical effect and decrease of SPAP were achieved.
Pneumonol Alergol Pol 1996
PMID:[Very low doses of tissue plasminogen activator in treatment of acute massive pulmonary embolism]. 918 92

43-year old woman, with considerable overweight had been admitted to Intensive Medical Care Unit with suspicion of pulmonary embolism (PE). The patient had the limb immobilized in gypsum for last several weeks. This episode was tangled with recurrent thrombosis of deep veins in the left limb, treated with heparin and oral anticoagulants irregularly without sufficient control. Taking into consideration the data of anamnesis, clinical picture and the results of ECG, chest X-ray, gasometric and echocardiographic examination we got much closer to the recognition of PE. Our suspicion of PE was confirmed by the result of pulmonary angiography. Indications for thrombolytic treatment (r-tPA) had been established. During the following hours considerable improvement of general state was observed. The therapy was continued with constant drip infusion of heparin. No prolongation of therapeutic PTT was observed. The deficit of AT III was diagnosed. In this situation the patient was given AT III to obtain normalization of its level and therapeutic extension of PTT. Therefore there were settled indications for the operation of uterus with myoma changes. As the rich thrombolytic material in the leg's vein was found the patient was implanted LGM Filter, with excellent prophylactic effect (no PE in perioperative period). The clinical course of our case enabled to present most of diagnostic, therapeutic and preventive methods applied in venous thromboembolism.
Pneumonol Alergol Pol 1996
PMID:[Massive pulmonary artery embolism complicated by acute pulmonary heart disease]. 918 93

23 consecutive patients were enrolled in the study, 21 after deep venous thrombosis, in 40% complicated by pulmonary embolism, and 2 with mechanical prosthetic heart valves with contraindications to oral anticoagulation. All of them received fraxiparine s.c. in doses of 7500 U anti-Xa daily, from at least 9 to 24 months. Fraxiparine was well tolerated. Re-thrombosis or signs of pulmonary embolisation as well as bleeding complications have not been observed. Long-term subcutaneous administration of fraxiparine is an effective and safe alternative for the prophylaxis of thromboembolism in cases with contraindication to oral anticoagulation, although the danger of osteoporosis should be considered.
Pol Arch Med Wewn 1997 Jan
PMID:[Long-term prophylaxis of thromboembolism and fraxiparin]. 923 51

Antiphospholipid-protein syndrome (APS) comprises venous and arterial thrombosis, spontaneous abortion and thrombocytopenia in patients with antiphospholipid-protein antibodies (APA). Such antibodies are detected by immunoenzymatic (ELISA) methods (e.g. anticardiolipin antibodies-ACL) or coagulation assays (lupus anticoagulant-LA). APS in patients showing other symptoms of autoimmune disease is called secondary antiphospholipid-protein syndrome. The aim of the study was to find relation between history of thrombosis and APA in a group of patients with lupus erythematosus and lupus-like disease. Lupus anticoagulant was detected by a three step procedure using phospholipid dependent clotting assays and anticardiolipin antibodies were measured by ELISA. We studied 95 subjects (91 women, 4 men) suffering from lupus erythematosus (67 patients) and lupus-like-disease (28 patients). Lupus anticoagulant was found in 26, anticardiolipin antibodies IgG in 34 and IgM in 27 subjects. In a retrospective study 40 thrombotic events were detected in 36 patients; deep vein thrombosis in 19, pulmonary embolism in 7, ischaemic CNS events in 13 and myocardial infarction in one. Thrombosis was present more often in subjects with LA (61%) and ACL IgG (52%) than in subjects without these antibodies (24%) (p = 0.004 and 0.015, respectively). ACL IgM antibodies were not related to thrombotic episodes. The ACL IgG antibodies and LA are helpful in identifying subjects at risk factors of venous and arterial thrombosis among patients suffering from lupus erythematosus and lupus-like disease.
Pol Merkur Lekarski 1996 Nov
PMID:[Prevalence of thrombosis in secondary antiphospholipid-protein syndrome]. 927 2


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>